ABSTRACT: Two-stage revision treatment of prosthetic joint infection (PJI) frequently employs the use of a temporary bone cement spacer loaded with multiple antibiotic types. Tobramycin and vancomycin are commonly used antibiotics in cement spacers, however, there is no consensus on the relative concentrations and combinations that should be used. Therefore, the purpose of this study was to investigate the influence of dual antibiotic loading on the total antibiotic elution and compressive mechanical properties of acrylic bone cement. Varying concentrations of tobramycin (0-3 g) and vancomycin (0-3 g) were added either alone or in combination to acrylic cement (Palacos R), resulting in 12 experimental groups. Samples were submerged in 37˚C saline for 28 d and sampled at specific time points. The collected eluent was analyzed to determine the cumulative antibiotic release. In addition, the cement's compressive mechanical properties and porosity were characterized. Interestingly, the cement with the highest concentration of antibiotics did not possess the best elution properties. Cement samples containing both 3 g of tobramycin and 2 g vancomycin demonstrated the highest cumulative antibiotic release after 28 d, which was coupled with a significant decrease in the mechanical properties and an increased porosity. The collected data also suggests that tobramycin elutes more effectively than vancomycin from cement. In conclusion, this study demonstrates that high antibiotic loading in cement does not necessarily lead to enhanced antibiotic elution. Clinically this information may be used to optimize cement spacer antibiotic loading so that both duration and amount of antibiotics eluted are optimized. ß
Prosthetic joint infection (PJI) is a devastating failure that can occur following total joint replacement with current incidence rates of 2.0 and 2.4% for hip and knee replacements (THA and TKA), respectively.
1 PJI can cause significant physical and emotional pain as well as long term disability to the patient while placing serious financial burdens on the healthcare system. For example, direct medical costs for revision arthroplasty resulting from infection are 2.8 times higher relative to aseptic loosening. 2 Although multiple strategies have been used to treat PJI, two-stage exchange arthroplasty remains the current gold standard of care. 3 In this procedure, the infected THA or TKA is removed and a temporary antibiotic spacer (static or articulating) fabricated from antibioticloaded acrylic bone cement is inserted into the hip or knee joint to provide high local concentrations of antibiotics.
Antibiotic spacers can be classified as either commercially available (i.e., preformed) or surgeon prepared. While commercially preformed spacers reduce intraoperative time, they do not allow the surgeon to customize the antibiotic regimen, add significant costs to the procedure, 4 and have not demonstrated improved antibiotic elution characteristics. 5 In contrast, surgeon prepared spacers allow more flexibility in antibiotic choice and concentration that are added to the acrylic cement, thus allowing for the surgeon to tailor the antibiotic regimen to specific infecting organisms. Additionally, more than one antibiotic can simultaneously be added to the acrylic cement. 6 Currently, it is generally accepted that a combination of a glycopeptide (e.g., vancomycin) and aminoglycoside (e.g., tobramycin or gentamicin) are the optimal antibiotics for inclusion into acrylic bone cement spacers for PJI eradication. 7 The combination of two antibiotics results in a phenomenon known as passive opportunism, referring to a synergistic elution of one or both of the impregnated antibiotics resulting from increased PMMA porosity. 8 As expected, the magnitude of this synergistic effect is dependent on the relative loading ratios of the antibiotics. 9 However, despite the perceived advantages of using a combination of two antibiotics in cement, the practice of utilizing a single antibiotic type still persists, albeit rare. 10, 11 Many different antibiotic loading ratios have been previously studied ranging from low to high concentrations. 12 For example, Hart and Jones 13 used one gram of vancomycin per cement pack, Stevens et al. 14 incorporated 3.6 g tobramycin and 3 g vancomycin, and Haddad et al. 15 used 2.4-3.6 g tobramycin and 1-1.5 g vancomycin. Unfortunately, there is no current consensus on the ideal antibiotic loading to be used within a spacer. 7, 16 While the addition of high antibiotic concentrations is generally thought to correlate with high antibiotic elution, previous studies have shown that this is not always true. 17 Lower antibiotic loadings may provide the same level of antimicrobial action (i.e. concentrations above minimum inhibitory concentration) as high loadings, while minimizing the total cost of an exchange arthroplasty. Additionally, high loadings of antibiotics can have a detrimental impact on the mechanical properties of the acrylic bone cement, 17 which is of consequence since patients
Correspondence to: Joshua Slane (T: þ32-16338128; E-mail: slaneja@gmail.com) receiving a cement spacer can be either partial or fully weight-bearing following exchange arthroplasty. The purpose of this study was to investigate the influence of dual antibiotic loading on the antibiotic elution properties, compressive strength, and porosity of acrylic bone cement. To this end, two antibiotics commonly used to treat PJI, tobramycin and vancomycin, where incorporated at various concentrations into a commercially available bone cement. The total drug release of both antibiotics, the cement porosity, and the compressive mechanical properties were subsequently characterized.
MATERIALS AND METHODS

Cement Preparation
Palacos R bone cement (Heraeus Medical GmbH, Wehrheim, Germany) with a standard 2:1 polymer powder to liquid monomer ratio was used for all testing. To prevent potential batch-to-batch variation, multiple powder and monomer lots were combined together. In total, 12 different experimental groups were examined (Table 1) . Powdered tobramycin (APP Pharmaceuticals, Schaumburg, IL) and vancomycin (Novaplus, Lake Forest, IL) were lightly homogenized with a mortar and pestle and added to the liquid monomer, a technique known as "suspension" mixing. 18 The cement powder was then added and mixed by hand at atmospheric conditions according to the manufacturer's instructions. Upon reaching the dough phase, cement was spatulated into aluminum molds and allowed to cure for 20 min. The resulting cylindrical samples had a diameter of 6 mm and height of 12 mm. Following polymerization, samples were stored for 24 AE 2 h at ambient conditions.
Antibiotic Elution
To determine the antibiotic release from the cements, five samples per group were submerged in 10 ml of normal saline and stored in an incubator at 37˚C with constant shaking at 60 rpm. At specific time points (0.25, 1, 3, 5, 7, 14, 21, and 28 d), samples were removed from the fluid, gently washed with saline and transferred to 10 ml of fresh saline to maintain sink conditions. The eluent from the previous time point was collected and stored in cryotubes at À80˚C until the time of analysis. Prior to testing, all cement samples were sterilized with ethylene oxide and sterile conditions were maintained at all times.
Vancomycin concentrations in the collected eluents were quantified by high performance liquid chromatography (HPLC) using a Shimadzu detector (SPD-10AV, Tokyo, Japan) equipped with a Luna 18 C(2) column (150 mm Â 4.6 mm, 5 mm analytical column, heated to 50˚C, flow rate 1 ml/min). The isocratic mobile phase consisted of 50 mM KH 2 PO 4 -Acetonitrile (composite ratio, 85/15) and absorbance was measured at 210 nm. Standard curves, run daily, were constructed using known vancomycin concentrations and the overall system sensitivity was 0.480 mg/ml. Tobramycin elution was characterized by reversed-phase HPLC coupled with mass spectroscopy using a technique that has been previously described. 19 With this technique, the quantification limit for tobramycin was 0.625 mg/ml.
The relationship between time and total antibiotic release was described using four kinetic models: Korsmeyer-Peppas, 20 Lindner-Lippold, 21 Noyes-Whitney, 22 and the coupled mechanism. 23 The parameters of these models were estimated using an unconstrained nonlinear minimization of the sum of squared residuals (Matlab R2014b, The MathWorks Inc., Natick, MA). Note, the combined tobramycin/vancomycin data were used for kinetic analysis.
Material Characterization
All samples for mechanical testing were stored in 25 ml of saline at 37˚C for 28 d prior to testing. An electromechanical materials testing frame (Criterion C43.104, MTS Systems, Eden Prairie, MN) was used to conduct compression testing till failure, with force and displacement data collected at 200 Hz. Ten cylindrical samples per group were tested at a crosshead rate of 20 mm/min between stainless steel platens that were lubricated with mineral oil to reduce frictional end effects. Testing was conducted at ambient conditions, however, samples were kept wet and at 37˚C until immediately prior to testing to mitigate the effect of drying and temperature change. The compressive modulus was calculated from the linear portion of the stress-strain curve while the yield strength was determined using the 2% offset method, as described in ISO 5833. 24 The porosity of the cement groups was calculated using Archimedes' principle. 25 Five cylindrical samples per group were conditioned in a desiccator following initial sample preparation and monitored until a constant weight was achieved. Samples were then soaked in 50 ml of normal saline for 28 days at 37˚C. The wet mass and submerged mass of the samples were measured (precision of 0.01 mg) using a density determination kit (A&D Weighing, Adelaide, Australia) and the porosity calculated.
Statistical Analysis
Where applicable, results are presented as the mean AE standard deviation. Collected data were assessed for normality using the Shapiro-Wilk test. Mechanical testing data were found to deviate from a normal distribution and therefore a mixture of parametric and non-parametric analyses were used. The collected elution and porosity data were analyzed using one-way analysis of variance with Tukey's HSD for post hoc analysis. For mechanical testing data, Kruskal-Wallis tests were used with Dunn's nonparametric comparison for post hoc. An alpha value of 0.05 was used for all testing. All statistical analyses were conducted using commercially available software (SPSS 23, IBM, Armonk, NY).
Table 1. Composition of Cement Groups Tested in This Study
Group
Tobramycin ( 
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RESULTS
Antibiotic Elution
The total cumulative elution of vancomycin and tobramycin from Palacos is shown in Table 2 . Cement group T3V2 was found to elute the highest cumulative concentration of both antibiotics, with 2.41 AE 0.04 mg 2.95 AE 0.29 mg of vancomycin and tobramycin, respectively. These peak concentrations for both antibiotics were significantly greater (p < 0.001) relative to any other cement group. For groups containing only a single antibiotic, the cumulative elution of tobramycin was always higher compared to vancomycin. For cements containing the same concentration of each antibiotic (e.g., T1V1), the elution of tobramycin was always greater. The elution profiles of tobramycin and vancomycin are shown in Figures 1 and 2 . All cement groups exhibited a burst effect during the first 24 h following submersion. For cements containing lower concentrations of antibiotics, the elution profile tended to level off following the initial burst release. This finding was more pronounced for vancomycin elution compared to tobramycin. After 24 h following initial submersion, group T3V2 released both the highest concentration of tobramycin (846 AE 117 mg) and vancomycin (479 AE 74 mg). For tobramycin, group T3V2 always released a significantly (p < 0.01) higher concentration relative to all other cements at all time points. For vancomycin release, group T3V2 had significantly (p < 0.001) higher elution relative to all other groups except T3V3 (468 AE 25 mg). After 5 d submersion, the vancomycin elution from T3V2 was significantly (p < 0.05) higher than T3V3.
A substantial synergistic effect was observed in the cumulative elution profiles of the cements (Figs. 1 and  2 ). For example, group T3V0 eluted a total of 1.08 mg of 28 days. Incorporating 1 g of vancomycin resulted in an approximately 38% increase in the elution of tobramycin. Interestingly, this effect was primarily observed only for the elution of tobramycin. As seen in Figure 2 , incorporating 1 g of tobramycin into cement containing 3 g of vancomycin only increased the elution of vancomycin by 9.3%.
The mean elution rates of the tested cements are shown (on a log-log scale) in Figure 3 . Similar to the total cumulative elution, group T3V2 was found to exhibit the highest elution rate for both tobramycin and vancomycin. For tobramycin, the elution rate for group T3V2 was significantly (p < 0.01) higher than all other groups for all time points. In contrast, the vancomycin elution rate from group T3V2 was significantly (p < 0.001) higher relative to all other groups except T3V3. After 5 d however, the vancomycin elution rate from T3V2 was significantly (p < 0.05) higher than T3V3.
The combined vancomycin/tobramycin elution data were found to generally be well defined by the four The lack of a specific antibiotic in a group is indicated by an emrule. investigated kinetic models ( Table 3 ). The release component of the models, n, was often found to be 0.45 which suggests that the antibiotic elution profile is complex in nature and that a power law alone cannot be fully characterize the behavior. 26 The coupled mechanism model resulted in the best fit to the experimental data (based on the R 2 values), however, the zero value obtained frequently for the burst effect component makes physical interpretation difficult (these values could be an aberration from the curve fitting procedure). The Noyes-Whitney model found that increasing the amount of antibiotic within the cement increased the observed burst effect, as expected. With this model, the cement group T3V2 had the highest burst effect component, which correlates with the other findings of this study.
Material Characterization
The compressive modulus and compressive strength of the bone cements were significantly affected by the inclusion of antibiotics (Fig. 4) . All cement groups, except for T0V1.5, T0V3, and T1V1, had a significantly (p < 0.05) lower compressive modulus relative to the control cement. The largest reduction seen in modulus was for group T3V2 (1,084 AE 52 MPa), which had a 37% reduction relative to the control cement. For compressive strength, all cements except T1.5V0, T0V1.5, and T1V1, were significantly lower than the control cement. Additionally, the compressive strength of several cements was below the requirement established in ISO 5833, 24 as seen in Figure 4 . The incorporation of antibiotics significantly (p < 0.001) increased cement porosity after submersion in fluid for 28 d (Table 4 ). All cements containing antibiotics, regardless of the loading ratio, had significantly higher porosity relative to the control cement. Group T3V3 had the highest porosity level, however, this was not statistically different than group T3V2. A significant correlation was observed between cement porosity and tobramycin elution (p ¼ 0.003 and R 2 ¼ 0.745) and vancomycin elution (p ¼ 0.026 and R 2 ¼ 0.529), as seen in Figure 5 .
DISCUSSION
Understanding the passive opportunism phenomenon and synergistic elution that occurs with dual antibiotic loaded acrylic bone cement is of high clinical importance so that spacer construction for the treatment of PJI can be optimized. In this study, the antibiotic elution, compressive mechanical properties, and porosity of acrylic bone cement modified with various concentrations of tobramycin and vancomycin were characterized. The obtained results indicate that the relative concentration and ratio in which tobramycin and vancomycin are added determine the antibiotic elution and mechanical properties of the cement. The tobramycin/vancomycin combination T3V2 demonstrated the most optimal elution kinetics as well as the highest cumulative drug release over a 28 d period. Additionally, the same group showed the greatest decrease in compressive properties and increase in porosity following exposure to a fluidic environment. The release of antibiotics from bone cement is thought to be initially governed by surface characteristics of the cement while the long-term elution is dependent on the cement's bulk porosity 9, 27 ; increased porosity allows for a greater fluid uptake which dissolves the antibiotic trapped within the cement matrix. 28 Various soluble additives (fillers) have been incorporated into acrylic cement to increase the elution of antibiotics including bacterial cellulose, 29 xylitol, 30 ,31 chitosan, 32 and glycine, 33 among others. While several of these methods are effective at increasing antibiotic release, the fillers themselves do not have intrinsic antimicrobial action. With the use of ANTIBIOTIC ELUTION FROM ACRYLIC BONE CEMENT dual-loaded antibiotic bone cement, the second antibiotic acts as a soluble filler, increasing the elution of one or both antibiotics, yet simultaneously exerts an antimicrobial effect. 9 Moreover, the use of a glycopeptide and aminoglycoside, such as those used in this study, is particularly attractive for bone cement because of the potential antibiotic synergism against gram-positive bacteria and the ability to disrupt bacterial growth on the cement's surface. 34 Several previous studies have investigated the influence on cement properties following the incorporation of two antibiotics, with various results. Paz et al. 17 added various concentrations of cefazolin (2.5% wt/wt) and vancomycin (2.5, 5, and 10% wt/wt) into Palacos R þ G cement and found that the cement group with the highest antibiotic concentration did not elute the highest antibiotic level, similar to that observed in the current work. Interestingly, their study did not examine the elution of gentamicin, despite its inclusion in the cement by the commercial manufacturer. Bertazzoni Minelli et al. 35 added gentamicin and vancomycin to Cemex cement alone and in combination and interestingly observed a decrease in total antibiotic release while confirming a synergistic action with a bioassay. Cerretani et al. 36 found that the addition of 2 g of imipenem-cilastatin increased vancomycin elution from Palacos cement $50%. Work from Penner et al. 8 showed that incorporating 2.4 g tobramycin and 1 g vancomycin increased the antibiotic elution by 68% and 103%, respectively, relative to using a single antibiotic alone. In direct contrast, Klekamp et al. 37 reported that the addition of vancomycin decreased tobramycin elution, however, this was potentially attributed to the use of vacuum mixing in their study. One advantage of the current work in comparison to these previously performed studies is that a larger number of clinically relevant antibiotic combinations were prepared and the elution profiles were monitored over an extended period of time.
Results from this study indicate somewhat paradoxically that inclusion of higher antibiotic concentrations into acrylic bone cement does not necessarily lead to higher cumulative antibiotic elution. This was demonstrated in both the total antibiotic elution over the 28 day testing period and the initial antibiotic release; kinetic analysis of the cements indicated that group T3V2 had the greatest burst effect component relative to the other cements. Furthermore, collected data suggest that tobramycin elutes more effectively than vancomycin, a result that has been previously shown in another study. 37 The interrelationship between the drug/concentration combination and antibiotic release is complex. For example, the group T3V2 eluted 173% more tobramycin that group T3V0, while group T2V3 release 65% vancomycin than group T0V3. The exact mechanism behind this finding is currently unknown, with one potential explanation being that there are poorly understood structural changes occurring within the cement/antibiotic composite upon exposure to a fluidic environment. While acrylic cement does absorb a small weight percentage of water, it is a hydrophobic polymer. 38 Antibiotics incorporated within the cement matrix may not be dissolved due to the poor absorption properties of the cement. Additionally, differences in the molecular weights of the antibiotics, $467 g/mol and 1449 g/mol for tobramycin and vancomycin, respectively, could influence the elution properties, 37 since an increase in the molecular weight could inhibit the mobility of an antibiotic through the polymer matrix.
In this study, the mechanical properties were assessed after cements were submerged in saline and maintained at 37˚C for 28 d. This was done to replicate the in vivo conditions of bone cement. The ISO standard for mechanical characterization of bone cement 24 does not call for sample conditioning in a wet environment, and therefore cannot capture the dissolution process of antibiotics that occurs. For some bone cement varieties, antibiotics can actually increase the mechanical properties, 39 potentially because the antibiotics are stiffer than the polymer matrix and thus act as a reinforcement. For this reason, measuring the dry mechanical properties were considered outside the scope of this study.
Significant decreases in the compressive modulus and strength were found with the addition of antibiotics to the cement, regardless of the antibiotic concentration. The extent of the relative change was dependent upon the type and concentration of antibiotic. Moreover, the inclusion of tobramycin had a greater impact on the compressive properties. For example, group T3V0 had a significantly lower modulus and strength relative to group T0V3. This result is supported by the finding that cements containing only tobramycin had a greater porosity than those with only vancomycin. An increase in porosity, which causes a net loss in load-carrying cross sectional area and forms stress concentration sites, typically reduces the mechanical properties of the cement. 40 The majority of patients undergoing two-stage exchange arthroplasty for PJI treatment have the antibiotic-cement spacer in situ for a limited period of time ($6 weeks to 3 months). During this time frame, patients are instructed to place minimal weight on the affected extremity, therefore, it is unlikely that the observed decrease in cement mechanical properties is of primary clinical relevance for spacer construction. However, as several of the tested combinations of antibiotics significantly reduced mechanical properties below the All cements had significantly higher porosity relative to the control (T0V0).
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ISO standard, their use in total hip/knee arthroplasty following PJI eradication should be avoided. Several limitations of this study should be noted. First, only a single bone cement formulation was used and other cements could elicit different results. The chosen cement, Palacos, was used since it is one of the most popular bone cements worldwide. 41 Second, only two types of antibiotics were incorporated into the cement although others such as gentamicin are widely used in bone cement. Third, all cements were prepared using hand mixing at atmospheric conditions, however, vacuum mixing is often used clinically. This choice was made since vacuum mixing has been demonstrated to reduce antibiotic elution, 42 thought to result from a reduction in the cement's porosity. Fourth, the antibiotic was incorporated into the cement using the "suspension" mixing method, however, other methods do exist such as the no-mix, handstirred, and bowl-mixed methods. Despite this, previous work has demonstrated that the antibiotic incorporation method has no significant influence on cumulative antibiotic elution. 18 Fifth, the antimicrobial efficacy of the collected eluent was not measured and therefore extrapolating these results to the in vivo scenario should be done with caution.
From a clinical standpoint, the results from this study provide important data concerning the fabrication of cement spacers for the treatment of PJI; incorporating higher concentrations of antibiotics into the cement does not necessarily lead to enhanced drug elution. This could potentially reduce the amount of intraoperative antibiotics, which can add considerable cost to a revision procedure. While the cement group T3V2 was found to elute significantly greater antibiotics than all other combinations tested, future work should be undertaken that examines the antimicrobial activity and synergistic action of the cement eluent against clinically-relevant bacterial species obtained from patients undergoing PJI treatment.
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